ClinicalTrials.gg
RecruitingNCT06630221Updated Nov 20, 2026

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

A Phase 2 interventional study of Eltrombopag (EPAG) in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, sponsored by Abhay Singh, MD MPH. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Abhay Singh, MD MPH · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 20, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing eltrombopag in Myelodysplastic Syndromes — 1 open to participants now, 3 under way, none of them phase 3. eltrombopag · Myelodysplastic Syndromes.

Planned enrollment
9th of 13
25 · median 30
Started
2025
the only one that year
Phase 2
8 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Abhay Singh, MD MPH

Among the 13 studies testing eltrombopag in Myelodysplastic Syndromes, this one is the 9th largest by planned enrollment, is the only one that started in 2025, is one of 8 in phase 2, and was the 13th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

1 of the 13 studies testing eltrombopag in Myelodysplastic Syndromes is open now, in 1 country.

By country, each count listing its studies:

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing eltrombopag in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if a study drug called eltrombopag can improve the blood cell counts in patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with mutations in TET2 gene, observe changes in the TET2 gene over time, and evaluate the effectiveness of the treatment. TET2 gene is one of the most frequently mutated genes (altered parts of the DNA) in MDS and CMML.

Eltrombopag is a Food and Drug Administration (FDA) approved drug for the treatment of severe aplastic anemia and low levels of platelets in patients with persistent or chronic immune thrombocytopenia (ITP) and chronic hepatitis C. Eltrombopag is considered investigational (experimental) in this study because the FDA has not approved its use in the treatment of low-risk MDS or CMML. Eltrombopag is a drug that helps stimulate the body's process of making more platelets (small components of blood that help with clotting) by interacting with specific parts of cells. This interaction starts a series of signals that encourage the growth and development of the cells that produce platelets. It was found that this drug could stop the growth of TET2 mutated cells.

Read the detailed description

Epigenetic changes such as alterations in DNA methylation and histone modification play an important role in the pathophysiology of myelodysplastic syndromes (MDS). With the development of next-generation sequencing (NGS) platforms, it has become possible to identify genomic aberrations involved in the MDS epigenetics. Additionally, with the advances in therapeutic methods in MDS, several novel genomic aberrations have been reported to predict the effectiveness of specific treatment. It is becoming clear that genomic aberrations may offer more precise cancer phenotypes and help predict precise therapies for MDS patients (e.g. IDH1 and IDH2 inhibitors). TET2 gene is a member of the DNA methylation machinery and one of the most frequently mutated genes in MDS and chronic myelomonocytic leukemia (CMML; a disease entity similar to MDS with similar bone marrow dysplasia and accompanying cytopenias). TET DNA dioxygenases hydroxylate 5-methylcytosine (5mC) to 5-hydroxy-mC (5hmC), a process that leads to passive demethylation and thereby initiation of differentiation programs of hematopoietic stem cells (HSCs). TET2 mutations (TET2MT) often act as founder lesions for clonal hematopoiesis of indeterminate potential (CHIP). Our group has demonstrated that mutational exclusivity of TET2 and isocitrate dehydrogenases 1 and 2 (IDH1/2) result from production of a neomorphic natural TET2 inhibitor α-hydroxyglutarate (2HG). 2HG is selectively and synthetically lethal to TET2-deficient HSCs reliant for their survival on minimal residual dioxygenase activity supplied by less abundant TET1 and TET3. This observation inspired the idea of generating TET inhibitors as drugs selective for TET2 mutant (TET2MT) leukemia cells. Based on the structure of 2HG, investigator generated a more potent TETi76, and showed that this drug is indeed synthetically lethal to TET2MT and TET2 proficient cells. In search for alternative agents with suitable activity, investigator next performed a high throughput drug screen using an in vitro DNA dioxygenase assay. Among several hits, eltrombopag (EPAG) was unique, as it is already used in clinical practice as a thrombopoietin receptor (TPOR) agonist. Investigator showed that this agent inhibited growth of TET2MT cells in murine TET2MT models independent of its TPOR activity, and have determined its binding site and mode of action on TET dioxygenases.1 Since EPAG is an FDA approved drug with known toxicities and good tolerability, repurposing this agent as a TET inhibitor would greatly shorten the development time and thus rapidly provide a selective and well-tolerated drug for the therapy of patients with TET2MT MDS. Investigators have obtained granular molecular and response data from historical trials of EPAG/5Azacytidine in unselected MDS and aplastic anemia (AA) and were able to retrospectively assert that indeed those with TET2MT disease responded to EPAG therapy, resulting in decreased TET2MT clonal burden.

03

Conditions studied

  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia

Keywords

  • MDS
  • CMML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of signing the form.
  • Willing and able to adhere to the study visit schedule and other protocol requirements.
  • Established diagnosis of very low-, low-, or intermediate-risk MDS (IPSS-R \< 3.5) and \< 5% myeloblasts or CMML 0 (CMML-0, for cases with \< 2% blasts in PB and \< 5% blasts in bone marrow (BM)z,[14] with any one of the notable cytopenias as defined below:

    1. \< 10 g/dL prior to enrollment
    2. ANC \< 1.5×10\^9/L
    3. \< 100×10\^9/L
  • Must be , refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as EPOs, luspatercept, and HMAs (i.e., azacytidine or decitabine). Patients with del (5q) must have failed prior lenalidomide therapy.
  • TET2 mutation performed at a frequency of at least > 5%.
  • performance status of 0-2.
  • Adequate organ function, defined as:

    1. Serum total \< 2x , unless the subject has Gilbert's syndrome. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis. In these cases, approval from the study PI is required.
    2. greater than 30 mL/min based on the Cockroft-Gault estimation.
    3. Participants being enrolled on study on the basis of anemia, will only be eligible if folate, B12, serum iron, serum ferritin, total iron binding capacity, haptoglobin and peripheral smear within normal limits
    4. Hepatitis panel negative for Hep B and Hep C infection
    5. Negative for infection
  • Women of (WOCBP) may participate provided they have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test within 72 h of starting treatment.
  • WOCBP and males with partners who are WOCBP must agree to abstain from sexual intercourse or use effective (methods that result in \< 1% pregnancy rates) during eltrombopag therapy and for at least 7 days after the last eltrombopag dose. Males with partners who are WOCBP must agree to use a barrier method.

Exclusion criteria

Exclusion Criteria:

  • High- and Very High-risk MDS (per IPSS-R)
  • CMML 1-2
  • Prior HMA exposure
  • count > 200×10\^9/uL or leukocytosis of at least 25×10⁹/L
  • Marrow fibrosis (any grade)
  • Results of bone marrow within 1 month of study entry (screening bone marrow biopsy) indicating high-risk MDS or CMML-2.
  • Elevated LFTs (aminotransferases and ) > 2x
  • Pre-existing cardiovascular disease (e.g., known coronary artery disease with percutaneous intervention or stroke within the last year) or arrhythmia (e.g., atrial fibrillation) associated with an increased risk of thromboembolic events, unless deemed acceptable by the enrolling treating physician.
  • History of arterial or venous thromboembolism, and on anticoagulation.
  • Severe hepatic impairment ( Class C)
  • Recent history of cancer (i.e., within the past 5 years) with > 50% chance of cancer recurrence in the next 5 years
  • Current or prior history of hematologic
  • Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
  • Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.)
  • Positive direct Coombs test
  • Evidence of hypersplenism on physical exam
  • Pregnant or lactating (women)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Eltrombopag (EPAG)

    Enrolled participants will receive EPAG 50 mg daily, 2h prior to or after meals for 1 cycle

    Drug: Eltrombopag (EPAG)

Interventions

  • DrugEltrombopagStudies of EltrombopagEltrombopag pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    50 mg, 28-day cycles, 3 initial cycles + 12 cycles on extension arm (maximum of 15 cycles)

    Also known as: Promacta

06

What researchers measure

Primary outcomes

  1. Response Rate as assessed by hematologic response

    Response rate will be assessed to determine whether treatment with EPAG can induce a hematologic response. The different types of hematologic improvement are Erythroid response (non-transfusion dependent, Erythroid response (transfusion dependent), Platelet response (pretreatment, \> 20 × 109/L), Platelet response (pretreatment, \< 20 × 109/L), Neutrophil response, and Progression or relapse after HI (after reaching maximum dose, and on maximum dose for 12 weeks).

    Time frame: At end of treatment (approximately up to 12 weeks)

Secondary outcomes

  1. AML-free survival

    AML-free survival will be calculated using the Kaplan-Meier method

    Time frame: At end of treatment (approximately up to 12 weeks)

  2. Progression Free Survival

    Progression free survival will be calculated using the Kaplan-Meier method

    Time frame: At end of treatment (approximately up to 12 weeks)

  3. Change in TET2 mutation burden as measured by variant allele fraction.

    Change in mutant TET2 variant allele fraction

    Time frame: Baseline, end of cycle 3(28 days per cycle), end of treatment(approximately up to 12 weeks)

  4. Rates of robust response as measured by platelet count

    Robust response will be summarized with a frequency and 95% confidence interval.

    Time frame: Approximately at 24 weeks post administration of intervention

  5. Rates of robust response as measured by hemoglobin

    Robust response will be summarized with a frequency and 95% confidence interval.

    Time frame: Approximately at 24 weeks post administration of intervention

  6. Rates of robust response as measured by ANC

    Robust response will be summarized with a frequency and 95% confidence interval.

    Time frame: Approximately at 24 weeks post administration of intervention

07

Study locations

1 of 1 sites recruiting
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
    Cleveland, Ohio 44195, United States
    Recruiting
    • Abhay Singh, MD MPH · Contact
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in publication will be shared as a combined summary. Any individual outcomes published per subject will be de- identified utilizing the subject ID (e.g., dosing, demographics, adverse events, etc.)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data included in the peer reviewed publication will be publicly available starting 6 months after publication and will be available indefinitely. No raw data will be shared.

Access criteria: A peer-reviewed publication will be made available according to the publishing journal's specifications. CCF personnel will not share study data apart from that which has been published publicly.

Data sharing details ↗ · pubmed.ncbi.nlm.nih.gov

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2028, 30 months after the start.

Of 227 non-industry phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 116. This study's planned 30 months is below that.

Counting every sponsor, half of 279 studies reached it within 65 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2024
First posted
Oct 8, 2024
StartActual
Jun 17, 2025
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Nov 20, 2026
Sites
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute is now Recruiting
Nov 20, 2026
Contact
Study contact now listed: added T•••@ccf.org · •••8100. See the current contact
Nov 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute · Cleveland, United StatesContact added (no phone or email listed)
Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute is now Recruiting
    Contact Study contact now listed: added T•••@ccf.org · •••8100. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute · Cleveland, United StatesContact added (no phone or email listed)
    + 1 other change: verification date
  2. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06630221
Lead sponsor
Abhay Singh, MD MPH
Responsible party
Abhay Singh, MD MPH (Principal Investigator, Case Comprehensive Cancer Center) — Sponsor-investigator
First posted
Oct 8, 2024
Start date
Jun 17, 2025
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

Abhay Singh, MD, MPH
Contact
TaussigResearch@ccf.org
1-866-223-8100
Abhay Singh, MD, MPH
principal investigator · Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion